title: MicroRNA-mediated down-regulation of PRDM1/Blimp-1 in Hodgkin/Reed-Sternberg cells: a potential pathogenetic lesion in Hodgkin lymphomas.
abstract: PRDM1/Blimp-1, a master regulator in terminal B-cell differentiation, has been recently identified as a tumor suppressor target for mutational inactivation in diffuse large B-cell lymphomas of the activated B-cell type. Our studies here demonstrate that PRDM1/blimp-1 is also a target for microRNA (miRNA)-mediated down-regulation by miR-9 and let-7a in Hodgkin/Reed-Sternberg (HRS) cells of Hodgkin lymphoma (HL). MiRNA expression profiling by direct miRNA cloning demonstrated that both of these miRNAs are among the most highly expressed in cultured HRS cells. These miRNAs functionally targeted specific binding sites in the 3' untranslated region of PRDM1/blimp-1 mRNA and repressed luciferase reporter activities through repression of translation. In addition, high levels of miR-9 and let-7a in HL cell lines correlated with low levels of PRDM1/Blimp-1. Similar to their in vitro counterparts, the majority of HRS cells in primary HL cases showed weak or no PRDM1/Blimp-1 expression. Over-expression of miR-9 or let-7a reduced PRDM1/Blimp-1 levels in U266 cells by 30% to 50%, whereas simultaneous inhibition of their activities in L428 cells resulted in an approximately 2.6-fold induction in PRDM1/Blimp-1. MiRNA-mediated down-regulation of PRDM1/Blimp-1 may contribute to the phenotype maintenance and pathogenesis of HRS cells by interfering with normal B-cell terminal differentiation, thus representing a novel molecular lesion, as well as a potential therapeutic target in HL.
authors.affiliation: Department of Pathology and Laboratory Medicine, Joan and Sanford I. Weill Medical College of Cornell University, New York, New York 10021, USA.
authors.forename: Kui
authors.initials: K
authors.lastname: Nie
authors.forename: Mario
authors.initials: M
authors.lastname: Gomez
authors.forename: Pablo
authors.initials: P
authors.lastname: Landgraf
authors.forename: Jose-Francisco
authors.initials: JF
authors.lastname: Garcia
authors.forename: Yifang
authors.initials: Y
authors.lastname: Liu
authors.forename: Leonard H C
authors.initials: LH
authors.lastname: Tan
authors.forename: Amy
authors.initials: A
authors.lastname: Chadburn
authors.forename: Thomas
authors.initials: T
authors.lastname: Tuschl
authors.forename: Daniel M
authors.initials: DM
authors.lastname: Knowles
authors.forename: Wayne
authors.initials: W
authors.lastname: Tam
mesh_terms: D020413:3' Untranslated Regions; D015153:Blotting, Western; D045744:Cell Line, Tumor; D015536:Down-Regulation; D044127:Epigenesis, Genetic; D015870:Gene Expression; D020869:Gene Expression Profiling; D015972:Gene Expression Regulation, Neoplastic; D006689:Hodgkin Disease / Q000235:genetics* / Q000378:metabolism; D006801:Humans; D007150:Immunohistochemistry; D035683:MicroRNAs / Q000096:biosynthesis / Q000235:genetics*; D000074462:Positive Regulatory Domain I-Binding Factor 1; D014176:Protein Biosynthesis; D016539:Reed-Sternberg Cells / Q000378:metabolism*; D012097:Repressor Proteins / Q000096:biosynthesis / Q000235:genetics*; D020133:Reverse Transcriptase Polymerase Chain Reaction; D014162:Transfection
chemical_list: D020413:3' Untranslated Regions; D035683:MicroRNAs; D012097:Repressor Proteins; C487931:mirnlet7 microRNA, human; C087042:PRDM1 protein, human; D000074462:Positive Regulatory Domain I-Binding Factor 1